12.07.2024  17:30:18 Zm. +0,0940 Wolumen Bid17:49:03 Ask17:49:03 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
2,2260CHF +4,41% 458 650
Obrót: 1,02 mln
2,1520Wolumen Bid: 220 2,2100Wolumen Ask: 9 569 -CHF - -

Opis działalności

Idorsia Ltd is an independent biopharmaceutical company specialized in the discovery and development of small molecule therapeutics to meet significant unmet medical needs. Idorsia has a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. Idorsia directly benefits from Actelion’s 19-year history and experience, inheriting Actelion’s established and validated drug discovery engine and a strong cross-section of its development organization. Idorsia’s pipeline will be developed by its own development organization. Headquartered in Allschwil, Switzerland, Idorsia was incorporated on 2 March 2017 and was launched on 16 June 2017.
 

Zarząd & Rada nadzorcza

CEO
Jean-Paul Clozel
Zarząd
André C. Muller, Martine Clozel, Guy Braunstein, Alberto Gimona
Rada nadzorcza
Jean-Paul Clozel, Mathieu Simon, Joern Aldag, Felix R. Ehrat, Srishti Gupta, Peter Kellogg, Sophie Kornowski, Sandy Mahatme, Bart Filius
 

Dane firmy

Nazwa: Idorsia Ltd
Adres: Hegenheimermattweg 91,CH-4123 Allschwil
Telefon: +41-58-8440000
Fax: -
E-mail: info@idorsia.com
Internet: https://www.idorsia.com
Przemysł: Służba zdrowia
Sektor: Przemysł Farmaceutyczny
Podsektor: Przemysł Farmaceutyczny
Koniec roku finansowego: 31.12
Free float: -
Data IPO: 16.06.2017

Relacje inwestorskie

Nazwa: Andrew C. Weiss
Telefon: +41-58-8441010
Fax: -
E-mail: investor.relations@idorsia.com

Główni akcjonariusze

Inne
 
65,00%
Jean-Paul & Martine Clozel
 
25,00%
Cilag Holding AG
 
5,00%
UBS Group AG
 
5,00%